195 results on '"Belachew S"'
Search Results
2. Histopathologic patterns of female genital tuberculosis with clinical correlation: a 10-year (2013–2022) retrospective cross-sectional study
3. Natalizumab improves ambulation in relapsing−remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM
4. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
5. Progression to disability milestones in multiple sclerosis patients treated with natalizumab in the clinical practice setting: EP2141
6. Assessment of disability status with longterm natalizumab treatment in the STRATA study: EP1151
7. Patients who switch to natalizumab have better outcomes than those who continue on the same platform therapy after a relapse: OS4202
8. After a relapse, patients who switch to natalizumab have better outcomes than those who switch between platform therapies: OS4203
9. RELATIONSHIP BETWEEN BASELINE TREATMENT HISTORY AND POSTBASELINE RELAPSES AND SERIOUS ADVERSE EVENTS IN NATALIZUMAB-TREATED PATIENTS WITH MULTIPLE SCLEROSIS (MS): TYSABRI® OBSERVATIONAL PROGRAM (TOP): SC315
10. Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis
11. Patterning Chronic Active Demyelination in Slowly Expanding/Evolving White Matter MS Lesions
12. Smartphone-based remote assessment of upper extremity function for multiple sclerosis using the Draw a Shape Test
13. Long-term safety and impact of natalizumab on disease activity and disability progression in patients with relapsing-remitting MS in clinical practice: TYSABRI® Observational Program (TOP): SC301
14. Long-term Reduction in Brain MRI Disease Activity and Atrophy after 5 years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis
15. PND18 - PROGRESSION OF DISABILITY IN PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS: A RETROSPECTIVE COHORT STUDY USING DATA FROM THE MSBASE REGISTRY AND A CONTEXTUALISATION WITH AN EXISTING NATURAL HISTORY DATASET
16. Effectiveness of Pictogram intervention in identification and reporting adverse drug reactions in Naïve HIV patients in Ethiopia
17. Evaluation of no evidence of progression using composite outcome measures, in patients with primary progressive multiple sclerosis in the ORATORIO trial
18. Natalizumab improves ambulation in relapsing−remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM
19. [Therapeutic armamentarium in neurology: the birth of a new era]
20. A corrected version of the Timed-25 Foot Walk Test with a dynamic start to capture the maximum ambulation speed in multiple sclerosis patients
21. Long-Term Safety and Efficacy and Association between Baseline Treatment History and Postbaseline Relapses in Multiple Sclerosis Patients Treated with Natalizumab in the TYSABRI(R) Observational Program (TOP) (P04.134)
22. Assessment of Baseline Characteristics, Treatment Efficacy, and Serious Adverse Events among Natalizumab-Treated MS Patients without Prior Treatment (P06.172)
23. Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated PML
24. Severe liver dysfunction in a patient with multiple sclerosis: the guilty party is not always the disease-modifying therapy
25. The effectiveness of pictogram intervention in the identification and reporting of adverse drug reactions in naïve HIV patients in Ethiopia: a cross-sectional study
26. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents
27. 129 Developmental regulation of neurotransmitters- and neuropeptides-induced responses in oligodendroglial cells cultured IN VITRO
28. Astroglia-released factor shows similar effects as benzodiazepine inverse agonists
29. Belgian Fabry study: prevalence of Fabry disease in a cohort of 1000 young patients with cerebrovascular disease.
30. The role of community pharmacists in patient counseling and health education: a survey of their knowledge and level of involvement in relation to type 2 diabetes mellitus
31. Pattern of chemotherapy-related adverse effects among adult cancer patients treated at Gondar University Referral Hospital, Ethiopia: a cross-sectional study
32. Preferred information sources and needs of cancer patients on disease symptoms and management: a cross-sectional study
33. Inappropriate prescribing of antithrombotic therapy in Ethiopian elderly population using updated 2015 STOPP/START criteria: a cross-sectional study
34. Management of children’s acute diarrhea by community pharmacies in five towns of Ethiopia: simulated client case study
35. Evaluation of preceptors and skills achievement by clinical pharmacy clerkship students during their clinical rotations at University of Gondar, Ethiopia
36. Proliferative generation of mammalian auditory hair cells in culture
37. Astroglia-Released Factor with Negative Allosteric Modulatory Properties at the GABA~A Receptor: Evidence from Binding Studies
38. Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS
39. The inhibition of cyclin-dependent kinases induces differentiation of supernumerary hair cells and Deiters' cells in the developing organ of Corti
40. Therapeutic armamentarium in neurology: The birth of a new era,L'Arsenal thérapeutique en neurologie: Une nouvelle ère voit le jour
41. Comparative efficacy of first-line natalizumab versus IFNb or glatiramer acetate in relapsing MS
42. Can a negative allosteric modulation of GABA(A) receptor kill neurons?
43. Neurotransmitter-mediated regulation of CNS myelination: a review
44. Phenotypical characterization of alpha-galacatosidase A gene mutations in a large Fabry disease screening program in stroke in the young
45. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents
46. Efficacy and Treatment Persistence of First-line Natalizumab vs. Interferon beta or Glatiramer Acetate in relapsing MS
47. The impact of pharmacist-led medication therapy management on medication adherence in patients with type 2 diabetes mellitus: a randomized controlled study
48. Period 2 regulates neural stem/progenitor cell proliferation in the adult hippocampus
49. Period 2 regulates neural stem/progenitor cell proliferation in the adult hippocampus.
50. Preliminary validity of the Draw a Shape Test for upper extremity assessment in multiple sclerosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.